Trial Profile
Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2015
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- 09 Sep 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 14 Mar 2013 New trial record